Epigenetics Drugs & Diagnostic Technologies Market To Reach $39.2 Billion By 2030

Epigenetics Drugs & Diagnostic Technologies Market Growth & Trends

The global epigenetics drugs & diagnostic technologies market size is expected to reach USD 39.2  billion by 2030, registering a CAGR of 14.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising incidence of cancer with epigenetic modification base is projected to drive the market growth.

Diagnostic firms are focused on developing new treatments such as antibodies specific for detection of epigenetic modifications and advanced kits for effective detection of biomarkers. It is likely to encourage pharmaceutical firms to partner for development of new advanced treatments which will further accelerate the market growth.

Presence of a large number of products under clinical trials and their projected commercialization is likely to boost the market. For instance, Eli Lilly’s Ramucirumab have been approved by the U.S. Food and Drug Administration (FDA) to be used in combination with Folfiri for the treatment of metastatic colorectal cancer.

Introduction of technologically advanced products in this space is mostly focused on detection of methylation markers associated with cancer development. For example, Epigenomics introduced Epi proLung BL Reflex Assay which helps in lung cancer diagnosis by determining methylation of SHOX2 biomarker gene.

 Request a free sample copy or view report summary: Epigenetics Drugs & Diagnostic Technologies Market Report

Epigenetics Drugs & Diagnostic Technologies Market Report Highlights

• Diagnostics products and services dominated the market and accounted for the largest revenue share of 94.9% in 2023 attributed to the increasing prevalence of chronic diseases and cancer, advancements in technology, and a rising geriatric population.

• Drugs are expected to grow at a CAGR of 10.9% over the forecast period.

• Oncology led the market and accounted for the largest revenue share of 69.1% in 2023 owing to the high prevalence of cancer among people across the world, and the surging number of cancer-related deaths results in the segment growth.

• Non-oncology application is expected to grow at a CAGR of 15.5% over the projected years. This growth is driven by the stringent R&D programs initiated by private organizations and biopharmaceutical companies.

• North America epigenetics drugs & diagnostic technologies market dominated the global market and accounted for the largest revenue share of 41.5% in 2023. North America is further expected to grow due to prospective growth, increasing awareness about personalized medicine, and increasing investment in the healthcare sector.

• The epigenetic drugs and diagnostic technologies market in Asia Pacific is anticipated to grow at a CAGR of 15.7% over the forecast period.

Epigenetics Drugs & Diagnostic Technologies Market Segmentation

Grand View Research has segmented the epigenetics drugs & diagnostic technologies market on the basis of on product & service, application, and region:

Epigenetics Drugs & Diagnostic Technologies Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnostics

  • Reagents

  • Kits

    • Chip Sequencing Kit

    • Whole Genomic Amplification Kit

    • Bisulfite Conversion Kit

    • RNA Sequencing Kit

    • Others

  • Instruments

  • Enzymes

  • Services

• Drugs

  • Histone Deacetylase (HDAC) Inhibitors

  • DNA Methyltransferase (DNMT) Inhibitors

  • Others

Epigenetics Drugs & Diagnostic Technologies Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Solid Tumors

  • Liquid Tumors

• Non-oncology

  • Inflammatory Diseases

  • Metabolic Diseases

  • Infectious Diseases

  • Cardiovascular Diseases

  • Others

Epigenetics Drugs & Diagnostic Technologies Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Epigenetics Drugs & Diagnostic Technologies Market

• Hoffmann-La Roche Ltd.

• Thermo Fisher Scientific Inc.

• Eisai Co., Ltd.

• Novartis AG

• ELEMENT BIOSCIENCES

• Cantata Bio

• Illumina, Inc.

• Promega Corporation.

• Abcam Limited.

• Merck KGaA